These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 17159191)

  • 1. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing.
    Tercyak KP; Peshkin BN; Brogan BM; DeMarco T; Pennanen MF; Willey SC; Magnant CM; Rogers S; Isaacs C; Schwartz MD
    J Clin Oncol; 2007 Jan; 25(3):285-91. PubMed ID: 17159191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.
    Graves KD; Peshkin BN; Halbert CH; DeMarco TA; Isaacs C; Schwartz MD
    Breast Cancer Res Treat; 2007 Sep; 104(3):321-9. PubMed ID: 17066320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer.
    Hamilton JG; Genoff MC; Salerno M; Amoroso K; Boyar SR; Sheehan M; Fleischut MH; Siegel B; Arnold AG; Salo-Mullen EE; Hay JL; Offit K; Robson ME
    Breast Cancer Res Treat; 2017 Apr; 162(2):297-306. PubMed ID: 28150129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients.
    Tynan M; Peshkin BN; Isaacs C; Willey S; Valdimarsdottir HB; Nusbaum R; Hooker G; O'Neill SC; Jandorf L; Kelly SP; Heinzmann J; Kelleher S; Poggi E; Schwartz MD
    Breast Cancer Res Treat; 2020 Feb; 180(1):177-185. PubMed ID: 31894446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical and financial implications of genetic counseling and requests for concurrent prophylactic mastectomy.
    Murphy RX; Adkinson JM; Namey T; Eid S; Bleznak A
    Ann Plast Surg; 2010 May; 64(5):684-7. PubMed ID: 20395792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result.
    Metcalfe KA; Eisen A; Poll A; Candib A; McCready D; Cil T; Wright F; Demsky R; Mancuso T; Sun P; Narod SA
    Ann Surg Oncol; 2021 Sep; 28(9):4967-4973. PubMed ID: 33761021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile?
    Tesson S; Richards I; Porter D; Phillips KA; Rankin N; Costa D; Musiello T; Marven M; Butow P
    Breast; 2017 Feb; 31():233-240. PubMed ID: 27969575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
    Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA
    Breast Cancer Res Treat; 2010 Apr; 120(3):715-23. PubMed ID: 19669874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic mastectomy for the prevention of breast cancer.
    Lostumbo L; Carbine N; Wallace J; Ezzo J
    Cochrane Database Syst Rev; 2004 Oct; (4):CD002748. PubMed ID: 15495033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
    Lodder LN; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Seynaeve C; van Geel AN; Tilanus MM; Bartels CC; Verhoog LC; Brekelmans CT; Burger CW; Niermeijer MF
    Breast Cancer Res Treat; 2002 May; 73(2):97-112. PubMed ID: 12088120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should the use of contralateral prophylactic mastectomy be increasing as it is?
    Wood WC
    Breast; 2009 Oct; 18 Suppl 3():S93-5. PubMed ID: 19914552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact.
    Wevers MR; Hahn DE; Verhoef S; Bolhaar MD; Ausems MG; Aaronson NK; Bleiker EM
    Patient Educ Couns; 2012 Oct; 89(1):89-95. PubMed ID: 22543000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
    J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.
    Schwartz MD; Lerman C; Brogan B; Peshkin BN; Halbert CH; DeMarco T; Lawrence W; Main D; Finch C; Magnant C; Pennanen M; Tsangaris T; Willey S; Isaacs C
    J Clin Oncol; 2004 May; 22(10):1823-9. PubMed ID: 15067026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
    Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
    J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
    Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
    Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women.
    Bresser PJ; Seynaeve C; Van Gool AR; Brekelmans CT; Meijers-Heijboer H; van Geel AN; Menke-Pluijmers MB; Duivenvoorden HJ; Klijn JG; Tibben A
    Plast Reconstr Surg; 2006 May; 117(6):1675-82; discussion 1683-4. PubMed ID: 16651934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study.
    Brandberg Y; Sandelin K; Erikson S; Jurell G; Liljegren A; Lindblom A; Lindén A; von Wachenfeldt A; Wickman M; Arver B
    J Clin Oncol; 2008 Aug; 26(24):3943-9. PubMed ID: 18711183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.